Kenn Daratha, PhD
Credit: WSU Spokane
Findings from a recent study presented at the American Society of Nephrology Kidney Week 2023 are calling attention to an increased prevalence of major adverse kidney disease events among patients with diabetes and chronic kidney disease (CKD).
Patients with CKD who had baseline estimated glomerular filtration rate (eGFR) and albuminuria measurements available were more frequently categorized as having greater Kidney Disease Improving Global Outcome (KDIGO) risk, which was associated with an increased prevalence of major adverse kidney disease events.1
“We found incredibly high rates for major adverse kidney events in a dose-dependent response by eGFR and albuminuria. This really validates the KDIGO heat map, which helps us identify the more severe cases of CKD and the corresponding event rate,” said Kenn Daratha, PhD, of Providence Medical Research Center, in an interview with HCPLive Nephrology.
According to the US Centers for Disease Control and Prevention, an estimated 1 in 3 adults with diabetes also has CKD.2 The American Diabetes Association recommends urinary albumin and eGFR be assessed in people with type 1 diabetes with a duration ≥5 years and…
